RPS6KA2

Ribosomal Protein S6 Kinase A2

Gene Information Card

Symbol RPS6KA2
Full Name Ribosomal Protein S6 Kinase A2
Gene Type Protein coding
Chromosomal Location 6q27
NCBI Gene ID 6196 ncbi.nlm.nih.gov/gene/6196
Ensembl ID ENSG00000171234
UniProt ID Q15349
OMIM ID 601685
HGNC ID 10432
Aliases RSK3, MAPKAPK1C, S6K-alpha2, p90-RSK3

Description

RPS6KA2 encodes a member of the RSK (ribosomal S6 kinase) family of serine/threonine kinases. This kinase acts downstream of the MAPK/ERK signaling cascade and phosphorylates multiple substrates involved in cell growth, proliferation, differentiation, and survival. It is widely expressed and has been implicated in various cancers and developmental disorders.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Coffin-Lowry syndrome Loss-of-function mutations in RPS6KA2 impair RSK3 activity, disrupting MAPK signaling and leading to intellectual disability and skeletal abnormalities. OMIM #303600; ClinVar pathogenic variants
Non-small cell lung cancer Overexpression and activating mutations in RPS6KA2 promote cell proliferation and resistance to apoptosis via enhanced ERK signaling. COSMIC; PMID: 23481259
Breast cancer Amplification of RPS6KA2 locus and increased RSK3 expression correlate with poor prognosis and tamoxifen resistance. PMID: 21536682; COSMIC
Ovarian cancer RPS6KA2 mutations and copy number gains contribute to tumor progression and chemoresistance. COSMIC; PMID: 22037554

Expression Profile

Tissue Expression
Tissue nTPM level
Brain 12.5 High
Heart 8.3 Medium
Lung 6.1 Medium
Liver 4.2 Low
Kidney 7.8 Medium
Testis 15.2 High
Cell Line Expression
Cell Line nTPM Notes
HEK293 10.5 High expression
HeLa 8.9 Medium expression
A549 7.2 Medium expression
MCF7 6.8 Medium expression
K562 5.1 Low expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.1124G>A (p.Arg375Gln) Missense <0.1% Reduced kinase activity; associated with Coffin-Lowry syndrome
c.1450C>T (p.Arg484Trp) Missense <0.1% Loss of function; intellectual disability
c.1960G>A (p.Glu654Lys) Missense 0.2% Gain of function; observed in lung adenocarcinoma
c.2113A>G (p.Thr705Ala) Missense 0.1% Unknown effect; reported in breast cancer
Mutation functional classification

Loss of Function (LOF)

Missense mutations in the kinase domain (e.g., Arg375Gln, Arg484Trp) reduce or abolish RSK3 activity, impairing downstream MAPK signaling and leading to Coffin-Lowry syndrome.

Gain of Function (GOF)

Activating mutations (e.g., Glu654Lys) enhance RSK3 kinase activity, promoting cell proliferation and survival in cancers.

Dominant Negative (DN)

No dominant-negative mutations have been reported for RPS6KA2.

Pathways

MAPK signaling pathway (KEGG: hsa04010)
mTOR signaling pathway (KEGG: hsa04150)
ErbB signaling pathway (KEGG: hsa04012)
Signaling by RSK (Reactome: R-HSA-444257)

Protein Summary

RPS6KA2 (RSK3) is a 733-amino acid serine/threonine kinase with two kinase domains. It is activated by ERK1/2 phosphorylation and phosphorylates substrates such as ribosomal protein S6, GSK3B, and transcription factors (CREB, c-Fos). RSK3 regulates cell cycle progression, translation, and survival. Dysregulation is linked to cancer and neurodevelopmental disorders.

Related Products

Product name Cat.No. Species Gene ID
RPS6KA2 Knockout HEK293 Cell Line EDJ-KQ231 Human 6196 Details Get a Quote
RPS6KA2 Knockout HCT 116 Cell Line EDJ-KQ19405 Human 6196 Details Get a Quote
RPS6KA2 Knockout HeLa Cell Line EDJ-KQ19406 Human 6196 Details Get a Quote
RPS6KA2 Knockout A-549 Cell Line EDJ-KQ62853 Human 6196 Details Get a Quote
Displaying Records 1 To 4 Of 4 Records
Contact Us
*
*
*
*
How did you hear about us: